Just the Facts: Percheron Hits Milestone in Duchenne Drug Trial | ASX:PER, OTC:PERCF

Proactive Investors17:43 ET

Percheron Therapeutics Advances Phase 2b Muscular Dystrophy Clinical Trial; Shares Down 3%

MT NewswiresDec 1 23:08 ET

Percheron Therapeutics Price Target Cut 7% to A$0.25/Share by Wilsons

Dow JonesNov 7 16:19 ET · Ratings

Percheron Therapeutics to Raise AU$13 Million via Share Placement; Shares Slump 35%

MT NewswiresOct 17 21:57 ET

Percheron Therapeutics Ltd: Percheron Receives $2.35 million R&D Tax Incentive Rebate

ASXOct 7 18:37 ET · Announcements

Percheron Therapeutics Validates Effectivity of Autoimmune Epilepsy Medication in Animal Study

MT NewswiresSep 3 03:18 ET